• Managed and directed special projects at Chairman' assignment• Assisted the IPO project, including market assessments, the BP and prospectus formulation, and roadshows as the Chief Marketing Officer• Coordinated international IVD sales of during pandemic: market survey, workflow establishment, resource allocation to meet dynamic requirements in a global emergency • manage the drug manufacturing plan for the clinical development, including the management of the CDMO, troubleshooting of manufacturing issues, project timeline management and budget control

Numbers of Subordinate: 3-4Responsibility:• Conducted fundamental technical and market assessments of potential products and propose strategic plan to fulfill the regulatory requirement of market approval and to accelerate product launch. • Formulated business strategies and developed collaboration models with local or global pharmaceutical partners for early research, developing or commercial products.• Managed projects and contracts, as well as controlled the budget and timeline by coordinating internal and external parties.• Established the international connections and explored collaboration opportunities at the global and domestic conferences/business activities.• Monitored the clinical development of H7N9 vaccine as the Medical AdvisorAchievement: • Completed the Phase I/II clinical development of H7N9 pandemic influenza vaccine with team members. The results has been published. • Completed collaboration agreements with global partners for early research, developing and commercial products.

Numbers of Subordinate: 8-10Responsibility:• Directed the development of pandemic influenza vaccines and supported the clinical development of other vaccines • Identified the potential partners for the design of the vaccine factory and prepared all technical information to initiate the conceptual factory design. • Maintained the successful communication with global partners in Korea, Japan, India, Thailand, and Europe, and prepared related business proposals and legal documents (MOU, term sheet, agreement) for collaboration. • Reviewed the technical documents, and assisted the patent application. Achievement: • Completed the Phase I clinical development of H5N1 pandemic influenza vaccine with team members.• Completed contract negotiation and signing of two license agreements and one patent application.• Participated in the planning of the groundbreaking ceremony of the vaccine factory as the main contact window for all distinguished guests.

Numbers of Subordinate: 8-10Responsibility:• Directed all vaccine development including R&D, GMP production, preclinical and clinical development, and leaded the team to achieve the milestones of each project.• Managed for all contracts, including contract negotiation, schedule control, resource allocation, cross-functional communication. • Kept good communicate with the Center of Drug Evaluation (CDE) and sharped the roadmap of vaccine development. • Reported to the board routinely, updated the progress of each project, and achieved consensus on overall business strategies with the board• Explored potential business opportunities and conducted the market surveyAchievement: • Completed the license agreement. • Completed R&D, production, preclinical development of two pandemic vaccines. • Compiled the chemistry, manufacturing and control (CMC) document for the investigational new drug (IND) application of H5N1 pandemic influenza vaccine.

Responsibility:• Evaluated potential products (small molecules and biologics), including patents, medical aspects (preclinical and clinical), CMC, regulation, market, and pharmacoeconomics.• Managed the preclinical studies, i.e. to design animal experiments, work with external parties (CRO or research teams)

PI: Dr. Andrew Hua-Jun Wang, Director of IBC • Managed the lab daily operation• Assisted experiments by crystallizing several essential proteins for functional studies, including phytase (myo-inositol hexaphosphate hydrolase), Sac7d and Sso10b (from Sulfolobus achaeabacteria) and its mutants.